Skip to content
CompletedPhase 2Results posted

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

NCT02106325 · NYU Langone Health

Closed to entry
Status
Not accepting participants
Phase 2
Phase
21
Target enrolment
2
Study sites
1 US states

What it is testing

Summary

Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment for people with Major Depressive Disorder. This study plans to explore the potential that Ketamine's rapid antidepressant action holds for improving outcomes in patients presenting to the Emergency Department with severe depression. Since this is a controlled trial we will use an IV of Ketamine or and equivalent volume of Diphenhydramine. Subjects will be randomly assigned to receive Ketamine or Benadryl. Investigators will then compare measures of mood pre- and post-infusion in the Emergency Department. To supplement self-reported measures of depressive symptoms(e.g. mood), investigators will obtain objective measures of the biological aspects of Major Depressive Disorder.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Evaluate the Effects of Ketamine on Depressive Symptomatology by Measuring Change in Score on the Montgomery-Asberg Depressive Rating Scale

    Measured over Baseline and 16 weeks

  • Beck Depression Inventory-II (BDI-II)

    Measured over 120 min post-infusion

  • Hamilton Depression Scale (Ham-D)

    Measured over 4-6 hours post-infusion

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Medically stable as determined by the medical physician * Meets criteria for Major Depressive Disorder (MDD) based on a structured clinical Interview (MINI International Neuropsychiatric Interview). * Reports symptoms of severe depression at the time of presentation, defined as a score of 24 or greater on the MADRS. * Patients for whom a psychiatric evaluation and disposition decision has been made by emergency psychiatry staff to admit to an inpatient psychiatric unit at Bellevue Hospital Center or NYU Tisch Hospital. * Each subject must have a level of understanding sufficient to sign an informed consent stating that the treatment being offered is not FDA approved for the treatment of depression and is being provided as an off-label option. Exclusion Criteria: * Pregnancy * Inability to read or understand English * Current clinical signs of intoxication or delirium at time of study intervention * Overdose, within previous 24 hours, of any agent which would impair ketamine metabolism * Lifetime misuse/abuse of ketamine, phencyclidine (PCP),or related substances * Lifetime history of psychotic spectrum illness * First-degree relative with history of psychotic illness * Lifetime diagnosis of borderline personality disorder, or as confirmed by assessment using items #90-104 of the SCID-II (for DSM-IV). * Subjects with clinically significant abnormal findings as determined by medical history, physical examination, vital signs (blood pressure, heart rate, and respiration rate), O2 saturation measure, 12-lead ECG, clinical laboratory tests (CBC, chemistry panel, thyroid function tests), urine drug screen, and urine pregnancy test (for females of childbearing potential only). * Clinically unstable medical, surgical or neurological conditions at ED presentation * History of stroke or intracranial hypertension * History of glaucoma * Subjects with one or more seizures without a clear and resolved etiology * Current NMDA antagonist medications (eg. Amantadine, Rimantadine, Lamotrigine, Memantine, Dextromethorphan) * Known hypersensitivity to ketamine or amantadine * Anti-psychotic medications (Typicals or Atypicals), with the exception of low-dose quetiapine (total daily dose of 100mg or less). * Actively trying to commit suicide, even in a hospital setting * Current homicide risk * Unable or unwilling to give informed consent according to HIC guidelines * Unable or unwilling to provide 2 contact phone numbers or be followed up per study protocol. * Previous enrollment in this study. * Concurrent enrollment in a research protocol investigating experimental pharmacologic treatments for depression at this or any other institution.

Where

2 study sites

FacilityCityRegionCountry
Bellevue Hospital CenterNew YorkNew YorkUnited States
NYU Langone Medical Center/Tisch HospitalNew YorkNew YorkUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02106325 on ClinicalTrials.gov →

Last updated in the registry 2018-09-14. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits